Associated tags: Erosion (morphology), Blepharitis, NovaBay Pharmaceuticals, Health, NYSE, Pharmaceutical, Optical, Biotechnology, Cosmetics, NBY, Retail, Pharmaceutical industry, Women, Consumer
Locations: UNITED STATES, NORTH AMERICA, CALIFORNIA
NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
Key Points:
- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY) announces that it will report financial results for the three months ended March 31, 2024 after market close on Thursday, May 9, 2024 and will hold an investment community conference call that day beginning at 4:30 p.m. Eastern time.
- Callers who pre-register will be emailed conference details and unique Registration ID to gain immediate access to the call and bypass the live operator.
- Those who choose not to pre-register can access the live conference call by dialing the following and requesting conference call ID# 85516:
888-500-3691 from within the U.S.
646-307-1951 from outside the U.S.
- The live webcast of the conference call also will be available on the Events section of the Company website.
Online Retail,
Pharmaceutical,
Family,
Optical,
Consumer,
Retail,
Marketing,
Women,
Biotechnology,
Communications,
Medical Supplies,
Health,
SMS,
Automation,
News,
Social media,
NBY,
Mobile phone NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products.
Key Points:
- NovaBay® Pharmaceuticals, Inc. (NYSE American: NBY), a company developing and commercializing high-quality eyecare and wound care products, announces a new and enhanced marketing program that includes text message communications (SMS) and targeted email programs aimed at enhancing the Avenova® brand while engaging with customers to drive online sales of Avenova products.
- The new and enhanced programs build upon the Company’s past highly productive marketing programs through proprietary channels including social media and email to cost-efficiently enhance customer loyalty and reach new prospective customers.
- “SMS provides an additional, immediate touchpoint with our customers and we are encouraged by the strong initial results.
- “The new SMS program builds on the incredible success we’ve had with our email and social media marketing programs to date,” he added.
(NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity.
Key Points:
- (NYSE American: NBY) announces that on April 18, 2024 it received a notice from the NYSE American LLC stating that the Company is below compliance with the NYSE American continued listing standards set forth in Sections 1003(a)(ii) and (iii) of the NYSE American Company Guide pursuant to stockholders equity.
- The Company intends to submit a plan to regain compliance to the NYSE American within the prescribed timeframe.
- The notice from the NYSE American has no immediate effect on the listing or trading of the Company’s common stock, and the common stock will continue to trade on the NYSE American.
- The notice does not affect the Company’s ongoing business operations or its reporting requirements with the Securities and Exchange Commission (SEC).
Retrieved on:
Wednesday, April 17, 2024
Communications,
Health,
Social Media,
Pharmaceutical,
Optical,
Biotechnology,
Social media,
Pinterest,
NBY,
Optometry,
Ophthalmology,
Marketing,
Beauty,
Knowledge (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023.
Key Points:
- (NYSE American: NBY) reports preliminary net revenue for its eyecare and wound care business for the first quarter of 2024 of $2.6 million, a 13% increase from the first quarter of 2023.
- This increase was achieved with lower sales and marketing expenses, and is attributed primarily to social media marketing programs aimed at consumer sales of the Company’s lead product, Avenova Antimicrobial Lid & Lash Solution.
- “We started 2024 with strong revenue growth from our core eyecare business while reducing marketing spend by capitalizing on our e-marketing expertise,” said Justin Hall, CEO of NovaBay.
- “Investing in direct-to-consumer marketing to leverage our clinical pedigree is a modern approach to the pharmaceutical industry’s traditional sales model.
Retrieved on:
Wednesday, March 13, 2024
Clobetasol,
NBY,
Physician,
Inflammation,
Patient,
Food and Drug Administration,
NovaBay Pharmaceuticals,
Pain,
FDA,
Ophthalmology,
Food,
Pharmaceutical industry EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
Key Points:
- EMERYVILLE, Calif. and NEW YORK, March 13, 2024 (GLOBE NEWSWIRE) -- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Eyenovia, Inc. (Nasdaq: EYEN) announced the signing of a co-promotion agreement to commercialize prescription ophthalmic products to eyecare professionals across the U.S.
- Under the agreement, NovaBay will market Eyenovia’s clobetasol propionate ophthalmic suspension 0.05% (“Clobetasol”), a steroid indicated for the treatment of inflammation and pain following ocular surgery, through its U.S. physician-dispensed channel.
- Eyenovia acquired the U.S. commercial rights to clobetasol propionate ophthalmic suspension 0.05% from Formosa Pharmaceuticals in August 2023.
- This co-promotion agreement reflects our shared commitment to bring scientifically developed, cutting-edge and high-quality ophthalmic products to physicians and the patients they treat.”
Biotechnology,
Pharmaceutical,
Optical,
Health,
Research and development,
PIN,
Growth,
NBY,
G&A,
Co-promotion,
Amazon (company),
OTC,
Marketing,
NovaBay Pharmaceuticals,
Pharmaceutical industry (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
Key Points:
- (NYSE American: NBY) reports financial results for the three and 12 months ended December 31, 2023 and provides a business update.
- Net product revenue for the fourth quarter of 2023 included $2.8 million from the eyecare and wound care segment, and $0.9 million from the skincare segment.
- Gross margin on net product revenue for the fourth quarter of 2023 was 49%, compared with 48% for the fourth quarter of 2022.
- Research & development (R&D) expenses also decreased for the fourth quarter of 2023 to $4 thousand, versus $66 thousand for the prior-year period.
Cosmetics,
Medical Supplies,
Retail,
Health,
Pharmaceutical,
Optical,
Biotechnology,
Webcast,
PIN,
NovaBay Pharmaceuticals,
NBY Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
Key Points:
- Callers who pre-register will be given a conference passcode and unique PIN to gain immediate access to the call and bypass the live operator.
- Participants may pre-register at any time, including up to and after the call start time.
- Those who choose not to pre-register can access the live conference call by dialing the following and requesting the NovaBay Pharmaceuticals call:
833-816-1121 from within the U.S.
412-317-1862 from outside the U.S.
- The live webcast of the conference call also will be available on the Events section of the Company website.
Medical Supplies,
Women,
Other Health,
Family,
Biotechnology,
General Health,
Pharmaceutical,
Consumer,
Health,
Optical,
E-commerce,
Growth,
NBY,
Partnership,
COVID-19,
Inflammation,
Operating cost,
Sale,
Pain,
FDA,
Pharmaceutical industry “This sale will reduce our quarterly operating expenses and provide us with much-needed cash during this challenging capital market environment.
Key Points:
- “This sale will reduce our quarterly operating expenses and provide us with much-needed cash during this challenging capital market environment.
- Operating loss for the fourth quarter of 2023 is expected to be approximately $3.2 million, due primarily to the $2.7 million loss in the DERMAdoctor skincare segment.
- Cash used in operating activities for the consolidated company for the fourth quarter of 2023 was $0.3 million.
- The Company plans to report 2023 fourth quarter and full year financial results and to hold an investment community conference call in the coming weeks.
Retrieved on:
Tuesday, January 30, 2024
NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.
Key Points:
- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) announces a 64% increase in online subscription-based unit sales for its Avenova® Lid & Lash Spray Solution and a 38% increase in subscription-based customers in 2023 over the prior year on Amazon.com and Avenova.com.
- A substantial 24% of all online sales were from subscribers in 2023, up from approximately 14% in 2022.
- In addition, of the more than 13,000 customer reviews across all online channels, Avenova Spray averaged a 4.5-star overall rating.
- “Generating sales through the subscriber base provides efficient and consistent revenue, allowing us to better manage our sales and marketing spend.
Medical Supplies,
Marketing,
Communications,
Biotechnology,
Other Health,
Health,
Pharmaceutical,
General Health,
Optical,
NBY,
European,
General counsel,
NovaBay Pharmaceuticals,
Blepharitis,
Eyelash,
Irritation,
Sale,
Hypochlorous acid,
Inflammation,
Red,
Eyelid,
Cosmetics NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union.
Key Points:
- NovaBay Pharmaceuticals, Inc. (NYSE American: NBY) and Sonoma Pharmaceuticals, Inc. (Nasdaq: SNOA) today announced an agreement for the sale and marketing of Avenova®-branded products by Sonoma in the European Union.
- This agreement brings together NovaBay’s deep knowledge of eye care reflected in its Avenova brand with Sonoma’s expertise in distributing hypochlorous acid products overseas.
- “Sonoma has built a strong and growing presence in the European Union through a network of distributors and direct sales.
- “The EU market is comparable in size to the U.S., giving NovaBay the opportunity to double its sales of Avenova.
